Phenotypic Association Analyses With Copy Number Variation in Recurrent Depressive Disorder
Joint grant from the United Kingdom Medical Research Council and GlaxoSmithKline (Grant No. G0701420) and the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley National Health Service (NHS) Foundation Trust and Institute of Psychiatry, King's College London. This work presents independent research in part funded by the NIHR. Also supported by the Wellcome Trust Grant No. 086635 (JJHR); NIHR Specialist Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, King's College London (SCW); a Marie Curie Intra-European Fellowship within the 7th European Community Framework Programme (MRiv); European Commission Grant Agreement No. 115008 (RU, PM); and Canada Research Chairs program (http://www. chairs-chaires.gc.ca/) (RU). Dr. Aitchison holds an Alberta Centennial Addiction and Mental Health Research Chair, funded by the government of Alberta, Canada. The Genome Based Therapeutic Drugs for Depression study was funded by a European Commission Framework 6 grant, European Commission Contract Reference LSHB-CT-2003-503428, and GlaxoSmithKline. Genotyping was performed at the Centre Nationale De Genotypage, Evry, Paris. We acknowledge the contribution of phase 2 of the Wellcome Trust Case Control Consortium in providing access to control datasets from the 1958 British birth cohort and the National Blood Service cohort.